Shalini Sharp Sells 6,700 Shares of Ultragenyx Pharmaceutical Inc (RARE) Stock

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) CFO Shalini Sharp sold 6,700 shares of the firm’s stock in a transaction dated Thursday, June 7th. The shares were sold at an average price of $80.07, for a total value of $536,469.00. Following the transaction, the chief financial officer now owns 60,178 shares of the company’s stock, valued at $4,818,452.46. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shalini Sharp also recently made the following trade(s):

  • On Wednesday, May 30th, Shalini Sharp sold 13,000 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $70.17, for a total value of $912,210.00.

RARE stock traded up $3.47 during trading on Thursday, hitting $81.56. 653,100 shares of the company’s stock were exchanged, compared to its average volume of 547,232. The stock has a market cap of $3.97 billion, a price-to-earnings ratio of -10.87 and a beta of 1.97. Ultragenyx Pharmaceutical Inc has a 52-week low of $41.67 and a 52-week high of $82.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.81. The business had revenue of $10.68 million for the quarter, compared to analysts’ expectations of $56.58 million. During the same quarter in the previous year, the firm earned ($1.63) EPS. research analysts predict that Ultragenyx Pharmaceutical Inc will post -5.32 EPS for the current fiscal year.

A number of brokerages recently commented on RARE. BidaskClub cut Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, May 1st. ValuEngine upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. Cowen reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. Barclays upgraded Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $62.00 to $74.00 in a research note on Friday, May 11th. Finally, JMP Securities lifted their price objective on Ultragenyx Pharmaceutical from $70.00 to $74.00 and gave the company an “outperform” rating in a research note on Wednesday, April 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $70.06.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Covington Capital Management acquired a new position in Ultragenyx Pharmaceutical during the first quarter worth approximately $102,000. Rockefeller Capital Management L.P. acquired a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at approximately $108,000. Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 1,246.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 3,030 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at approximately $213,000. Finally, Xact Kapitalforvaltning AB acquired a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $205,000. 96.11% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply